Journal
Journal of Clinical Oncology
Publication Date
9-1-2024
Volume
42
Issue
25
First Page
2989
Last Page
2999
Document Type
Open Access Publication
DOI
10.1200/JCO.23.02625
Rights and Permissions
Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. J Clin Oncol. 2024 Sep 1;42(25):2989-2999. doi: 10.1200/JCO.23.02625. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Dzienis, Marcin; Oppelt, Peter; and et al., "Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): A single-arm phase IV trial." Journal of Clinical Oncology. 42, 25. 2989 - 2999. (2024).
https://digitalcommons.wustl.edu/oa_4/4076
Additional Links
Supplemental material is available for this article at publisher site.
